Mitochondrial DNA Copy Number Variations and Serum Pepsinogen Levels for Risk Assessment in Gastric Cancer
| Autor: | Alikhani, Mehdi, Saberi, Samaneh, Esmaeili, Maryam, Michel, Valérie, Tashakoripour, Mohammad, Abdirad, Afshin, Aghakhani, Arezoo, Eybpoosh, Sana, Vosough, Massoud, Mohagheghi, Mohammad Ali, Eshagh Hosseini, Mahmoud, Touati, Eliette, Mohammadi, Marjan |
|---|---|
| Přispěvatelé: | Institut Pasteur d'Iran, Réseau International des Instituts Pasteur (RIIP), Pathogenèse de Helicobacter / Helicobacter Pathogenesis, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Tehran University of Medical Sciences (TUMS), Academic Center for Education, Culture and Research (ACECR), This project was supported by an ACIP (Pasteur International Concerted Action) grant (ACIP2015-10) from Institut Pasteur Paris, and Grant #833 from Pasteur Institute of Iran, as partial fulfillment of MA Ph.D. dissertation (code: TP-9347). |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
serum pepsinogen DNA Copy Number Variations Full Length Stomach neoplasms DNA copy number variation [SDV.CAN]Life Sciences [q-bio]/Cancer MESH: Pepsinogen A MESH: Risk Assessment DNA Mitochondrial Risk Assessment Pepsinogen A Humans Lymphocytes MESH: Humans MESH: Middle Aged Helicobacter pylori gastric cancer MESH: DNA Mitochondrial MESH: Stomach Neoplasms Middle Aged MESH: ROC Curve Mitochondrial DNA MESH: Male mitochondrial DNA copy number ROC Curve Female MESH: DNA Copy Number Variations MESH: Lymphocytes MESH: Female Biomarkers |
| Zdroj: | Iranian Biomedical Journal Iranian Biomedical Journal, 2021, 25 (5), pp.323-33. ⟨10.52547/ibj.25.5.323⟩ |
| ISSN: | 1028-852X |
| DOI: | 10.52547/ibj.25.5.323⟩ |
| Popis: | Variations in mitochondrial DNA copy number (mtDNA-CN) of peripheral blood leukocytes (PBLs), as a potential biomarker for gastric cancer (GC) screening has currently been subject to controversy. Herein, we have assessed its efficiency in GC screening, in parallel and in combination with serum pepsinogen (sPG) I/II ratio, as an established indicator of gastric atrophy.The study population included GC (n = 53) and non-GC (n = 207) dyspeptic patients. The non-GC group was histologically categorized into CG (n = 104) and NM (n = 103) subgroups. The MtDNA-CN of PBLs was measured by quantitative real-time PCR. The sPG I and II levels and anti-H. pylori serum IgG were measured by ELISA.The mtDNA-CN was found significantly higher in GC vs. non-GC (OR = 3.0; 95% CI = 1.4, 6.4) subjects. Conversely, GC patients had significantly lower sPG I/II ratio than the non-GC (OR = 3.2; CI = 1.4, 7.2) subjects. The combination of these two biomarkers yielded a dramatic amplification of the odds of GC risk in double-positive (high mtDNA-CN-low sPGI/II) subjects, in reference to double-negatives (low mtDNA-CN-high sPGI/II), when assessed against non-GC (OR = 27.1; CI = 5.0, 147.3), CG (OR = 13.1; CI = 2.4, 72.6), or NM (OR = 49.5; CI = 7.9, 311.6) groups.The combination of these two biomarkers, namely mtDNA-CN in PBLs and serum PG I/II ratio, drastically enhanced the efficiency of GC risk assessment, which calls for further validations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|